Nanobodies uniquely possess the combined therapeutic advantages of mAbs and the targeting potential of nanoscale delivery. Their compact size enables enhanced tumor penetration and access to hidden and/or intracellular epitopes, while also granting high modularity for creating more complex constructs. Anti-EGFR (epidermal growth factor receptor) therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, demonstrate activity in a variety of tumor types.